Complementarity determining regions in SARS-CoV-2 hybrid immunity
peer-reviewed · Frontiers in Immunology · 2023
| Date | 2023-02-21 |
| Type | peer-reviewed |
| Venue | Frontiers in Immunology |
| Publisher | Frontiers Media SA |
| Contribution | downstream-application |
| DOI | 10.3389/fimmu.2023.1050037 |
| Citations (OpenAlex) | 5 |
Abstract
Pre-vaccination SARS-CoV-2 infection can boost protection elicited by COVID-19 vaccination and post-vaccination breakthrough SARS-CoV-2 infection can boost existing immunity conferred by COVID-19 vaccination. Such ‘hybrid immunity’ is effective against SARS-CoV-2 variants. In order to understand ‘hybrid immunity’ at the molecular level we studied the complementarity determining regions (CDR) of anti-RBD (receptor binding domain) antibodies isolated from individuals with ‘hybrid immunity’ as well as from ‘naive’ (not SARS-CoV-2 infected) vaccinated individuals. CDR analysis was done by liquid chromatography/mass spectrometry-mass spectrometry. Principal component analysis and partial least square differential analysis showed that COVID-19 vaccinated people share CDR profiles and that pre-vaccination SARS-CoV-2 infection or breakthrough infection further shape the CDR profile, with a CDR profile in hybrid immunity that clustered away from the CDR profile in vaccinated people without infection. Thus, our results show a CDR profile in hybrid immunity that is distinct from the vaccination-induced CDR profile.
Methods and tools
- SARS-CoV-2 hybrid immunity CDR profiling: LC-MS/MS profiling of complementarity determining regions of anti-RBD antibodies, partly by de novo sequencing, separates hybrid-immunity CDR profiles from vaccination-only ones.
Methods it uses
- PEAKS: Commercial DP-based de novo
Data deposited
- Complementarity Determining Regions in SARS-CoV-2 hybrid immunity — as deposited · PXD038849